VJHemOnc Podcast Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
Jul 1, 2024
Experts Toby Eyre and Lydia Scarfò discuss the latest updates in CLL treatment, including BTK and BCL2 inhibitor combinations, BTK degraders, and the role of epcoritamab in Richter’s transformation. They explore the trade-off between toxicity and efficacy, potential sequencing strategies, and promising results in heavily pretreated CLL patients, offering insights on future treatments and clinical trials.
Chapters
Transcript
Episode notes
1 2 3 4 5
Intro
00:00 • 4min
Exploring Different Drug Combinations in CLL Treatment with Focus on Toxicity and Efficacy Trade-offs
03:32 • 2min
Exploring BTK degraders and their potential in heavily pretreated CLL patients
05:51 • 2min
Exploring novel treatments and potential sequencing strategies for CLL
07:56 • 2min
Treatment Updates for Chronic Lymphocytic Leukemia
10:02 • 2min